Evidence map›Paper›PMID 38746871›Full record

ArticleVeterinary medicine international2024

Development and Evaluation of Monoclonal Antibodies against CBPP Antigen with the End Goal of Developing an ELISA Kit.

Lorato Ramathudi-Dunbar, Emmanuel Awosanya, Sanne Bodjo Charles, Ethel Chitsungo, Cisse Rahamatou Moustapha Boukary, Nick Nwankpa, Hassen Gelaw, Yebechaye Tessema, Gelagay Melesse A, Richard Rayson Sanga and 2 more

Abstract read
In one paragraph

Article in Veterinary medicine international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lorato Ramathudi-DunbarPan African University Life Sciences Institute Including Health and Agriculture (PAULESI), University of Ibadan, Ibadan, Nigeria.
Emmanuel AwosanyaPan African University Life Sciences Institute Including Health and Agriculture (PAULESI), University of Ibadan, Ibadan, Nigeria.
Sanne Bodjo CharlesAfrican Union Pan African Veterinary Vaccine Centre (AU-PANVAC), P.O. Box 1746, Debre Zeit, Ethiopia.
Ethel ChitsungoAfrican Union Pan African Veterinary Vaccine Centre (AU-PANVAC), P.O. Box 1746, Debre Zeit, Ethiopia.
Cisse Rahamatou Moustapha BoukaryAfrican Union Pan African Veterinary Vaccine Centre (AU-PANVAC), P.O. Box 1746, Debre Zeit, Ethiopia.
Nick NwankpaAfrican Union Pan African Veterinary Vaccine Centre (AU-PANVAC), P.O. Box 1746, Debre Zeit, Ethiopia.
Hassen GelawAfrican Union Pan African Veterinary Vaccine Centre (AU-PANVAC), P.O. Box 1746, Debre Zeit, Ethiopia.
Yebechaye TessemaAfrican Union Pan African Veterinary Vaccine Centre (AU-PANVAC), P.O. Box 1746, Debre Zeit, Ethiopia.
Gelagay Melesse AAfrican Union Pan African Veterinary Vaccine Centre (AU-PANVAC), P.O. Box 1746, Debre Zeit, Ethiopia.
Richard Rayson SangaPan African University Life Sciences Institute Including Health and Agriculture (PAULESI), University of Ibadan, Ibadan, Nigeria.
Adorbley BrightPan African University Life Sciences Institute Including Health and Agriculture (PAULESI), University of Ibadan, Ibadan, Nigeria.
Jean de Dieu BazikiAfrican Union Pan African Veterinary Vaccine Centre (AU-PANVAC), P.O. Box 1746, Debre Zeit, Ethiopia.ORCID https://orcid.org/0000-0001-7387-9915

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Contagious bovine pleuropneumonia (CBPP) is an infectious and contagious bacterial respiratory disease that affects cattle with significant economic losses to the African animal industry. The use of ELISA kits based on monoclonal antibodies (mAbs) will aid in quick and precise diagnosis of CBPP, contributing to disease control and prevention in cattle. Thus, this research aims to develop and evaluate monoclonal antibodies against CBPP (T1/44) antigen for use in ELISA kits for CBPP diagnosis. Hybridoma technology was used to develop monoclonal antibodies that recognize and bind to the CBPP (T1/44) antigen. The antibody-secreting hybridomas were produced after immunizing mice with purified CBPP antigens. The hybridomas were screened for high sensitivity, specificity, and liking to the antigen. The selected mAbs were assessed for sensitivity and specificity against CBPP antigen using different immunoassays, dot-blot, ELISA, and mouse mAb isotyping. The monoclonal antibodies were profoundly specific, with a higher hindrance to CBPP antigen (<0.50 OD) while lacking cross-reactivity to other antigens. The monoclonal antibodies could distinguish CBPP antigen at low concentrations, showing their high sensitivity (>80% PI). The isotyped mAbs of intrigued appeared to have a place in the IgG class. These identified monoclonal antibodies can be utilized to develop an ELISA kit for CBPP diagnosis, which would give a fast, precise, and cost-effective strategy for screening and checking CBPP in cattle herds.

Identifiers

PMID38746871
PMCPMC11093687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.